OAM
KRTX

Oppenheimer Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Oppenheimer Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,845
Closed -$900K – 1181
2023
Q4 		$900K Sell
2,845
-16
-0.6% -$3.11K 0.01% 736
2023
Q3 		$484K Sell
2,861
-10
-0.3% -$1.88K 0.01% 854
2023
Q2 		$623K Sell
2,871
-90
-3% -$19.3K 0.01% 807
2023
Q1 		$538K Buy
2,961
+929
+46% +$178K 0.01% 838
2022
Q4 		$399K Buy
2,032
+484
+31% +$104K 0.01% 909
2022
Q3 		$348K Buy
+1,548
New +$313K 0.01% 920

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Oppenheimer Asset Management's KRTX Position: Q1 2024 in Review

Oppenheimer Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,845 shares — an estimated $900K sold.

Oppenheimer Asset Management first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $900K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Oppenheimer Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Oppenheimer Asset Management sold 2,845 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $900K.
  • Oppenheimer Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Oppenheimer Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $900K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Oppenheimer Asset Management's 13F filing for Q1 2024, filed 7 May 2024.